Evidence map›Paper›PMID 38795051›Full record

ArticleInflammatory bowel diseases2025

Increasing Rates of Bowel Resection Surgery for Stricturing Crohn's Disease in the Biologic Era.

Kush Fansiwala, Ellen J Spartz, Andrew R Roney, Mary R Kwaan, Jenny S Sauk, Po-Hung Chen, Berkeley N Limketkai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Kush FansiwalaVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0003-2019-8002
Ellen J SpartzDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Andrew R RoneyVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Mary R KwaanDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jenny S SaukVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Po-Hung ChenDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-9865-1009
Berkeley N LimketkaiVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Funding

Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver DiseaseK23AA028297 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHEN, PO-HUNG (VICTOR) · 2020 to 2024
$991k
NIAAA NIH HHS K23 AA028297NIH HHS K23AA028297
6 · The paper itself

Abstract

backgroundThe era of biologics is associated with declining rates of surgery for Crohn's disease (CD), but the impact on surgery for stricturing CD is unknown. Our study aimed to assess nationwide trends in bowel resection surgery for obstruction in CD since the introduction of infliximab for CD in 1998.

methodsUsing the Nationwide Inpatient Sample, we performed a nationwide analysis, identifying patients hospitalized for CD who underwent bowel resection for an indication of obstruction between 1998 and 2020 (era of biologics). Longitudinal trends in all CD-related resections and resection for obstruction were evaluated. Multivariable logistic regression identified patient and hospital characteristics associated with bowel resection surgery for obstruction.

resultsHospitalizations for all CD-related resections decreased from 12.0% of all hospitalizations in 1998 to 6.9% in 2020, while hospitalizations for CD-related resection for obstructive indication increased from 1.3% to 2.0%. The proportion of resections for obstructive indication amongst all CD-related bowel resections increased from 10.8% in 1998 to 29.1% in 2020. In the multivariable models stratified by elective admission, the increasing year was associated with risk of resection for obstructive indication regardless of urgency (nonelective model: odds ratio, 1.01; 95% CI, 1.00-1.02; elective model: odds ratio, 1.06; 95% CI, 1.04-1.08).

conclusionsIn the era of biologics, our findings demonstrate a decreasing annual rate of CD-related bowel resections but an increase in resection for obstructive indication. Our findings highlight the effect of medical therapy on surgical rates overall but suggest limited impact of current medical therapy on need of resection for stricturing disease.

Indexed as

Biological ProductsCrohn DiseaseDigestive System Surgical ProceduresHospitalizationIntestinal ObstructionAdolescentAdultConstriction, PathologicFemaleFollow-Up StudiesHumansInfliximabMaleMiddle AgedUnited StatesYoung AdultBiological ProductsInfliximabbowel resectionCrohn’s diseaseCrohn’s strictureselective surgery

Identifiers

PMID38795051
PMCPMC11985397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.